Alirocumab after Acute Coronary Syndrome. Reply

Affiliations

¹ University of Colorado School of Medicine, Aurora, CO gregory.schwartz@ucdenver.edu.
² Hôpital Bichat, Paris, France.
³ State University of New York Downstate School of Public Health, Brooklyn, NY.

Comment

Gregory G Schwartz et al. N Engl J Med. 2019.

. 2019 May 23;380(21):2077.

doi: 10.1056/NEJMc1902955.

¹ University of Colorado School of Medicine, Aurora, CO gregory.schwartz@ucdenver.edu.
² Hôpital Bichat, Paris, France.
³ State University of New York Downstate School of Public Health, Brooklyn, NY.

No abstract available

Comment on

Alirocumab after Acute Coronary Syndrome.
Gao Y, Hou B. Gao Y, et al. N Engl J Med. 2019 May 23;380(21):2074-2075. doi: 10.1056/NEJMc1902955. N Engl J Med. 2019. PMID: 31116929 No abstract available.
Alirocumab after Acute Coronary Syndrome.
Alkhalil M. Alkhalil M. N Engl J Med. 2019 May 23;380(21):2075. doi: 10.1056/NEJMc1902955. N Engl J Med. 2019. PMID: 31116930 No abstract available.
Alirocumab after Acute Coronary Syndrome.
Lan NSR, Yeap BB, Fegan PG. Lan NSR, et al. N Engl J Med. 2019 May 23;380(21):2075-2076. doi: 10.1056/NEJMc1902955. N Engl J Med. 2019. PMID: 31116931 No abstract available.
Alirocumab after Acute Coronary Syndrome.
Ennezat PV, Hansen MR. Ennezat PV, et al. N Engl J Med. 2019 May 23;380(21):2076. doi: 10.1056/NEJMc1902955. N Engl J Med. 2019. PMID: 31116932 No abstract available.
Alirocumab after Acute Coronary Syndrome.
Pignatelli P, Camera M, Violi F. Pignatelli P, et al. N Engl J Med. 2019 May 23;380(21):2076. doi: 10.1056/NEJMc1902955. N Engl J Med. 2019. PMID: 31116933 No abstract available.